Mantle cell lymphoma: an update on management
Open Access
- 1 May 2006
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (suppl_4) , iv12-iv14
- https://doi.org/10.1093/annonc/mdj992
Abstract
Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy.Keywords
This publication has 17 references indexed in Scilit:
- High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and CytarabineJournal of Clinical Oncology, 2005
- Current Treatment Approaches for Mantle-Cell LymphomaJournal of Clinical Oncology, 2005
- Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response PathwaysJournal of Clinical Oncology, 2005
- Stem cell transplantation for mantle cell lymphoma: if, when and how?Bone Marrow Transplantation, 2005
- Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Journal of Clinical Oncology, 2005
- Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.Blood, 2004
- The role of idiotype vaccines in the treatment of human B-cell malignanciesExpert Review of Vaccines, 2004
- Integrating Monoclonal Antibodies into the Management of Mantle Cell LymphomaSeminars in Oncology, 2004
- Non-Hodgkin lymphomaThe Lancet, 2003
- Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free SurvivalJournal of Clinical Oncology, 2002